Indoco Remedies per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹3.43−₹10.70₹8.46₹10.53₹15.44
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹3.45−₹10.69₹8.45₹10.51₹15.42
₹101.76₹101.76₹110.79₹120.38₹111.58
₹206.79₹199.93₹180.48₹197.10₹181.08
—₹20.83₹10.29₹17.00₹19.41
₹4.84₹4.84−₹28.32−₹29.35−₹3.08
—₹0.21₹1.51₹2.25₹2.25
9.29.29.29.29.2
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDOCO₹213.75

Indoco Remedies Limited

· Pharma & Health
₹ CrorePeersSAIPARENTPANACEABIOHIKALWINDLASHESTERBIODCALSYNCOMFSOLARAMcap ₹1,973 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS15.4410.538.46-10.703.43
Diluted EPS15.4210.518.45-10.693.45
Book Value per Share111.58120.38110.79101.76101.76
Revenue per Share181.08197.10180.48199.93206.79
Cash Flow per Share19.4117.0010.2920.83—
Free Cash Flow per Share-3.08-29.35-28.324.844.84
Dividends per Share2.252.251.510.21—
Shares Outstanding (cr)9.29.29.29.29.2
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.